Table 1.
Groups | Biopsy at | Cases |
p53 |
Bcl-2 |
Bax |
Survivin |
Positive (%) | Positive (%) | Positive (%) | Positive (%) | |||
Control | 30th wk | 13 | 0 (0) | 0 (0) | 0 (0) | 4 (30.8) |
60th wk | 13 | 0 (0) | 0 (0) | 0 (0) | 5 (38.4) | |
90th wk | 13 | 0 (0) | 0 (0) | 0 (0) | 5 (38.4) | |
Trial | 30th wk | 35 | 0 (0) | 3 (8.6) | 2 (5.7) | 14 (40) |
60th wk | 35 | 21 (60)bd | 7 (20) | 10 (28.6)ac | 13 (37.1) | |
HCC | 35 | 25 (71.4)bd | 14 (40) | 25 (71.4)bde | 19 (57.1) |
P < 0.05,
P < 0.01 vs each stage control;
P < 0.05,
P < 0.01 vs experiment for 30 wk;
P<0.05 vs experiment for 30 wk.